Biomarin Pharmaceutical Earnings Estimate
| BMRN Stock | USD 69.44 1.16 1.64% |
Biomarin Pharmaceutical Revenue Breakdown by Earning Segment
By analyzing Biomarin Pharmaceutical's earnings estimates, investors can diagnose different trends across Biomarin Pharmaceutical's analyst sentiment over time as well as compare current estimates against different timeframes. As of the 17th of March 2025, Gross Profit is likely to grow to about 2.4 B. Also, Pretax Profit Margin is likely to grow to 0.20
Biomarin |
Biomarin Pharmaceutical Earnings Estimation Breakdown
The calculation of Biomarin Pharmaceutical's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Biomarin Pharmaceutical is estimated to be 0.6517 with the future projection ranging from a low of 0.71 to a high of 1.16. Please be aware that this consensus of annual earnings estimates for Biomarin Pharmaceutical is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.71 Lowest | Expected EPS | 1.16 Highest |
Biomarin Pharmaceutical Earnings Projection Consensus
Suppose the current estimates of Biomarin Pharmaceutical's value are higher than the current market price of the Biomarin Pharmaceutical stock. In this case, investors may conclude that Biomarin Pharmaceutical is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Biomarin Pharmaceutical's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 28 | 70.04% | 0.92 | 0.6517 | 2.21 |
Biomarin Pharmaceutical Earnings per Share Projection vs Actual
Actual Earning per Share of Biomarin Pharmaceutical refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Biomarin Pharmaceutical predict the company's earnings will be in the future. The higher the earnings per share of Biomarin Pharmaceutical, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Biomarin Pharmaceutical Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Biomarin Pharmaceutical, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Biomarin Pharmaceutical should always be considered in relation to other companies to make a more educated investment decision.Biomarin Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Biomarin Pharmaceutical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-20 | 2024-12-31 | 0.7386 | 0.92 | 0.1814 | 24 | ||
2024-10-29 | 2024-09-30 | 0.52 | 0.55 | 0.03 | 5 | ||
2024-08-05 | 2024-06-30 | 0.35 | 0.56 | 0.21 | 60 | ||
2024-04-24 | 2024-03-31 | 0.35 | 0.46 | 0.11 | 31 | ||
2024-02-22 | 2023-12-31 | 0.23 | 0.18 | -0.05 | 21 | ||
2023-11-01 | 2023-09-30 | 0.23 | 0.21 | -0.02 | 8 | ||
2023-07-31 | 2023-06-30 | 0.23 | 0.29 | 0.06 | 26 | ||
2023-04-26 | 2023-03-31 | 0.18 | 0.27 | 0.09 | 50 | ||
2023-02-27 | 2022-12-31 | -0.07 | -0.0013 | 0.0687 | 98 | ||
2022-10-26 | 2022-09-30 | -0.01 | -0.04 | -0.03 | 300 | ||
2022-08-03 | 2022-06-30 | 0.11 | 0.15 | 0.04 | 36 | ||
2022-04-27 | 2022-03-31 | 0.17 | 0.18 | 0.01 | 5 | ||
2022-02-23 | 2021-12-31 | -0.32 | -0.32 | 0.0 | 0 | ||
2021-10-27 | 2021-09-30 | -0.25 | -0.2 | 0.05 | 20 | ||
2021-07-28 | 2021-06-30 | -0.11 | 0.07 | 0.18 | 163 | ||
2021-04-29 | 2021-03-31 | -0.07 | 0.09 | 0.16 | 228 | ||
2021-02-25 | 2020-12-31 | -0.19 | 0.12 | 0.31 | 163 | ||
2020-11-05 | 2020-09-30 | 1.24 | 4.01 | 2.77 | 223 | ||
2020-08-04 | 2020-06-30 | -0.1 | -0.02 | 0.08 | 80 | ||
2020-04-29 | 2020-03-31 | 0.05 | 0.44 | 0.39 | 780 | ||
2020-02-26 | 2019-12-31 | -0.06 | 0.08 | 0.14 | 233 | ||
2019-10-23 | 2019-09-30 | 0.06 | 0.3 | 0.24 | 400 | ||
2019-08-01 | 2019-06-30 | -0.11 | -0.21 | -0.1 | 90 | ||
2019-04-25 | 2019-03-31 | -0.19 | -0.32 | -0.13 | 68 | ||
2019-02-21 | 2018-12-31 | -0.25 | -0.02 | 0.23 | 92 | ||
2018-10-25 | 2018-09-30 | -0.22 | -0.07 | 0.15 | 68 | ||
2018-08-02 | 2018-06-30 | -0.17 | -0.21 | -0.04 | 23 | ||
2018-04-25 | 2018-03-31 | -0.17 | -0.25 | -0.08 | 47 | ||
2018-02-22 | 2017-12-31 | -0.23 | -0.4 | -0.17 | 73 | ||
2017-10-26 | 2017-09-30 | -0.14 | -0.07 | 0.07 | 50 | ||
2017-08-02 | 2017-06-30 | -0.21 | -0.21 | 0.0 | 0 | ||
2017-05-04 | 2017-03-31 | -0.29 | -0.09 | 0.2 | 68 | ||
2017-02-23 | 2016-12-31 | -0.38 | -0.53 | -0.15 | 39 | ||
2016-10-27 | 2016-09-30 | -0.39 | -0.26 | 0.13 | 33 | ||
2016-08-04 | 2016-06-30 | -0.52 | 1.08 | 1.6 | 307 | ||
2016-04-28 | 2016-03-31 | -0.84 | -0.53 | 0.31 | 36 | ||
2016-02-25 | 2015-12-31 | 0.99 | 0.39 | -0.6 | 60 | ||
2015-10-29 | 2015-09-30 | -0.65 | -0.57 | 0.08 | 12 | ||
2015-08-03 | 2015-06-30 | -0.53 | -0.43 | 0.1 | 18 | ||
2015-04-30 | 2015-03-31 | -0.53 | -0.38 | 0.15 | 28 | ||
2015-02-25 | 2014-12-31 | -0.59 | -0.47 | 0.12 | 20 | ||
2014-10-23 | 2014-09-30 | -0.23 | -0.38 | -0.15 | 65 | ||
2014-07-30 | 2014-06-30 | -0.42 | -0.22 | 0.2 | 47 | ||
2014-05-01 | 2014-03-31 | -0.46 | -0.33 | 0.13 | 28 | ||
2014-02-26 | 2013-12-31 | -0.35 | -0.43 | -0.08 | 22 | ||
2013-10-24 | 2013-09-30 | -0.3 | -0.38 | -0.08 | 26 | ||
2013-07-25 | 2013-06-30 | -0.29 | -0.15 | 0.14 | 48 | ||
2013-04-25 | 2013-03-31 | -0.29 | -0.31 | -0.02 | 6 | ||
2013-02-21 | 2012-12-31 | -0.27 | -0.43 | -0.16 | 59 | ||
2012-10-25 | 2012-09-30 | -0.2 | -0.04 | 0.16 | 80 | ||
2012-08-01 | 2012-06-30 | -0.21 | -0.27 | -0.06 | 28 | ||
2012-04-26 | 2012-03-31 | -0.14 | -0.21 | -0.07 | 50 | ||
2012-02-16 | 2011-12-31 | -0.11 | -0.23 | -0.12 | 109 | ||
2011-10-27 | 2011-09-30 | -0.11 | -0.14 | -0.03 | 27 | ||
2011-07-28 | 2011-06-30 | -0.11 | -0.05 | 0.06 | 54 | ||
2011-04-28 | 2011-03-31 | -0.1 | -0.04 | 0.06 | 60 | ||
2011-02-17 | 2010-12-31 | -0.02 | 0.01 | 0.03 | 150 | ||
2010-10-28 | 2010-09-30 | -0.01 | 1.68 | 1.69 | 16900 | ||
2010-08-02 | 2010-06-30 | 0.03 | -0.01 | -0.04 | 133 | ||
2010-02-23 | 2009-12-31 | 0.01 | 0.05 | 0.04 | 400 | ||
2009-10-28 | 2009-09-30 | 0.01 | 0.06 | 0.05 | 500 | ||
2009-07-30 | 2009-06-30 | -0.01 | 0.01 | 0.02 | 200 | ||
2009-04-30 | 2009-03-31 | -0.12 | -0.13 | -0.01 | 8 | ||
2009-02-18 | 2008-12-31 | 0.26 | 0.21 | -0.05 | 19 | ||
2008-10-28 | 2008-09-30 | 0.03 | 0.01 | -0.02 | 66 | ||
2008-08-05 | 2008-06-30 | 0.03 | 0.04 | 0.01 | 33 | ||
2008-04-29 | 2008-03-31 | -0.05 | 0.02 | 0.07 | 140 | ||
2008-02-26 | 2007-12-31 | 0.04 | 0.03 | -0.01 | 25 | ||
2007-11-01 | 2007-09-30 | -0.1 | -0.05 | 0.05 | 50 | ||
2007-08-07 | 2007-06-30 | -0.06 | -0.04 | 0.02 | 33 | ||
2007-04-30 | 2007-03-31 | -0.11 | -0.1 | 0.01 | 9 | ||
2007-02-20 | 2006-12-31 | -0.13 | -0.11 | 0.02 | 15 | ||
2006-11-01 | 2006-09-30 | -0.13 | -0.08 | 0.05 | 38 | ||
2006-08-02 | 2006-06-30 | -0.11 | -0.02 | 0.09 | 81 | ||
2006-05-03 | 2006-03-31 | -0.21 | -0.13 | 0.08 | 38 | ||
2006-02-23 | 2005-12-31 | -0.22 | -0.2 | 0.02 | 9 | ||
2005-11-01 | 2005-09-30 | -0.28 | -0.21 | 0.07 | 25 | ||
2005-08-01 | 2005-06-30 | -0.35 | -0.33 | 0.02 | 5 | ||
2005-05-05 | 2005-03-31 | -0.35 | -0.35 | 0.0 | 0 | ||
2005-02-23 | 2004-12-31 | -0.33 | -0.23 | 0.1 | 30 | ||
2004-11-03 | 2004-09-30 | -0.36 | -0.4 | -0.04 | 11 | ||
2004-08-09 | 2004-06-30 | -0.29 | -0.28 | 0.01 | 3 | ||
2004-05-04 | 2004-03-31 | -0.31 | -0.31 | 0.0 | 0 | ||
2004-02-03 | 2003-12-31 | -0.38 | -0.4 | -0.02 | 5 | ||
2003-11-04 | 2003-09-30 | -0.39 | -0.33 | 0.06 | 15 | ||
2003-08-05 | 2003-06-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2003-05-05 | 2003-03-31 | -0.28 | -0.35 | -0.07 | 25 | ||
2003-02-09 | 2002-12-31 | -0.35 | -0.36 | -0.01 | 2 | ||
2002-10-31 | 2002-09-30 | -0.31 | -0.32 | -0.01 | 3 | ||
2002-08-01 | 2002-06-30 | -0.29 | -0.27 | 0.02 | 6 | ||
2002-05-07 | 2002-03-31 | -0.33 | -0.51 | -0.18 | 54 | ||
2002-02-25 | 2001-12-31 | -0.3 | -0.34 | -0.04 | 13 | ||
2001-10-26 | 2001-09-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2001-07-27 | 2001-06-30 | -0.26 | -0.3 | -0.04 | 15 | ||
2001-04-27 | 2001-03-31 | -0.26 | -0.26 | 0.0 | 0 | ||
2001-02-22 | 2000-12-31 | -0.33 | -0.28 | 0.05 | 15 | ||
2000-10-30 | 2000-09-30 | -0.29 | -0.23 | 0.06 | 20 | ||
2000-07-28 | 2000-06-30 | -0.27 | -0.19 | 0.08 | 29 | ||
2000-04-28 | 2000-03-31 | -0.26 | -0.34 | -0.08 | 30 | ||
2000-02-18 | 1999-12-31 | -0.26 | -0.26 | 0.0 | 0 | ||
1999-11-01 | 1999-09-30 | -0.22 | -0.24 | -0.02 | 9 |
About Biomarin Pharmaceutical Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Biomarin Pharmaceutical earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Biomarin Pharmaceutical estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Biomarin Pharmaceutical fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -194.7 M | -204.4 M | |
| Retained Earnings Total Equity | -833.1 M | -874.8 M | |
| Earnings Yield | 0.03 | 0.04 | |
| Price Earnings Ratio | 29.26 | 30.72 | |
| Price Earnings To Growth Ratio | 0.21 | 0.20 |
Pair Trading with Biomarin Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biomarin Stock
| 0.76 | ZVSA | ZyVersa Therapeutics | PairCorr |
| 0.69 | NKTX | Nkarta Inc Earnings Call This Week | PairCorr |
| 0.58 | PHVS | Pharvaris BV | PairCorr |
| 0.52 | MOLN | Molecular Partners | PairCorr |
| 0.49 | IMMX | Immix Biopharma | PairCorr |
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.449 | Earnings Share 2.21 | Revenue Per Share | Quarterly Revenue Growth 0.156 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.